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A published predictor model in a single-site cohort study (questionable dementia, QD) that contained episodic verbal memory
(SRT total recall), informant report of function (FAQ), and MRI measures was tested using logistic regression and ROC analyses
with comparable measures in a second multisite cohort study (Alzheimer’s Disease Neuroimaging Initiative, ADNI). There were
126 patients in QD and 282 patients in ADNI with MCI followed for 3 years. Within each sample, the diﬀerences in AUCs between
the statistical models were very similar. Adding hippocampal and entorhinal cortex volumes to the model containing AVLT/SRT,
FAQ,ageandMMSEincreasedtheareaunderthecurve(AUC)inADNIbutnotQD,withsensitivityincreasingby2%inADNIand
2%inQDforaﬁxedspeciﬁcityof80%.Conversely,addingepisodicverbalmemory(SRT/AVLT)andFAQtothemodelcontaining
age, Mini Mental State Exam (MMSE), hippocampal and entorhinal cortex volumes increased the AUC in ADNI and QD, with
sensitivity increasing by 17% in ADNI and 10% in QD for 80% speciﬁcity. The predictor models showed similar diﬀerences from
each other in both studies, supporting independent validation. MRI hippocampal and entorhinal cortex volumes showed limited
added predictive utility to memory and function measures.
1.Introduction
Mild cognitive impairment (MCI) often represents a tran-
sitional state between normal cognition and Alzheimer’s
disease (AD) [1, 2]. Accurate prediction of transition from
MCI to AD aids in prognosis and targeting early treatment
[3]. Episodic verbal memory impairment and informant
report of functional deﬁcits in complex social and cognitive
tasks are features of incipient AD, and impairment in these
domains is associated with transition from MCI to AD [4, 5].
Most biomarkers of MCI transition to AD are related to
the underlying disease pathology of amyloid plaques and
neuroﬁbrillary tangles [6]. Hippocampal and entorhinal
cortex atrophy on MRI scan of brain [7], parietotemporal
hypometabolism on 18FDG PET [8], increased amyloid up-
take using PET [9], and decreased amyloid beta-42 (Aβ42)
with increased tau/phospho-tau levels in the cerebrospinal
ﬂuid(CSF)[10,11]eachsigniﬁcantlypredicttransitionfrom
M C It oA D .T h ea p o l i p o p r o t e i nEε4 allele increases AD risk,
but is not a strong biomarker of transition from MCI to AD
[3].
In a meta-analysis, memory deﬁcits appeared to be supe-
rior to MRI hippocampal atrophy in predicting transition to
AD [12], but studies in the meta-analysis had highly variable
subject inclusion/exclusion criteria and assessment methods.
There has been a lack of direct head-to-head comparison
of clinical and neuroimaging predictors of transition across
diﬀerent studies.2 International Journal of Alzheimer’s Disease
In our single-site study (Questionable Dementia or QD
study) that evaluated and followed a broadly deﬁned sample
of patients with MCI, a published predictor model that
included speciﬁc cognitive, functional, olfactory, and MRI
measures strongly predicted transition to AD [3]. In the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) study,
cognitive and functional measures and several biomarkers
are assessed in samples of MCI, AD, and healthy control
subjects at baseline and serially during followup. In this
paper, the ﬁrst goal was to test the accuracy of a combination
of predictor variables derived from the QD study to predict
transition from MCI to AD in a completely independent
ADNI sample. The validation of speciﬁc predictor combina-
tions, rather than individual measures, has rarely been done
in independent samples. This is essential before speciﬁc cut-
points, and ranges for speciﬁc predictors in such models
can be developed with conﬁdence for eventual clinical
application. The second goal was to evaluate the relative
utility of clinical and MRI measures in predicting transition
from MCI to AD.
2. Methods
Patients with MCI in the QD and ADNI studies were in-
cluded, and patients with AD (ADNI) and healthy control
subjects(QDandADNI)wereexcluded.The3-yearfollowup
samples were chosen because most transitions occur to AD
within 3 years of clinical presentation [13].
2.1. QD Study. As previously reported, patients 41–85 years
old who presented with subjective memory complaints for
clinical evaluation to a Memory Disorders Clinic were eligi-
ble if they had a Folstein Mini-Mental State Exam (MMSE)
score ≥22 out of 30, memory impairment deﬁned as MMSE
recall ≤2/3 objects at 5 minutes or a Selective Reminding
Test (SRT) delayed recall score >1SD below norms, and
absence of a consensus diagnosis of dementia made by
two experienced raters [3]. Patients could also be included
if they had other cognitive and functional deﬁcits. This
study began before criteria for MCI were published [1, 2].
Baseline MCI subtype using the criterion of >1.5SD below
norms on cognitive tests was determined post hoc by using
age, education, and sex-based regression norms derived
from 83 healthy control subjects [4]. Using this approach,
73% of patients met the Peterson criteria for single or
multidomain amnestic MCI, and this subsample was also
compared to ADNI. The presence of speciﬁc neurological
or major psychiatric disorders led to exclusion [3]. Patients
were followed every 6 months for up to 9 years, and the two
raters made a consensus diagnosis at each time point. The
samplecomprised148patientswithMCIatbaseline,and126
patients were in the 3-year followup sample.
2.2. ADNI Study. Data were obtained from the ADNI study
(http://adni.loni.ucla.edu/), a project launched in 2003 by
the National Institute on Aging, the National Institute of
Biomedical Imaging and Bioengineering, the Food and
Drug Administration, private pharmaceutical companies,
and non-proﬁt organizations as a $60 million, 5-year public-
privatepartnership.Theprimarygoalistotestwhetherserial
magnetic resonance imaging, positron emission tomogra-
phy, other biological markers, and clinical and neuropsy-
chological assessment can be combined to measure the
progression of MCI and early AD.
Participants 55–90 years old were enrolled if they had
at least 6 years of education, spoke English or Spanish,
agreed to longitudinal followup and neuroimaging tests,
had single or multidomain MCI by the Petersen criteria
with MMSE scores between 24 and 30, a memory com-
plaint veriﬁed by informant, an abnormal memory score
(1.5SD below age-adjusted cutoﬀ) on the Logical Memory
II subscale (delayed paragraph recall) from the Wechsler
Memory Scale-Revised,and absence of a dementia diagnosis.
All participants had a Geriatric Depression Scale score of
<6 and a modiﬁed Hachinski score of ≤4. For a more
detailed account of the inclusion/exclusion criteria, please
see http://www.adni-info.org/.R a t e r sa te a c hs i t em a d e
consensus diagnoses at six-month intervals that included
an evaluation of transition from MCI to AD, which was
r e v i e w e db yac e n t r a lc o m m i t t e e .D a t aw e r eo b t a i n e df r o m
ADNI on October 31, 2010. Of 394 individuals with MCI
at baseline evaluation, 282 subjects completed 3 years of
followup.
2.3. Comparable Baseline Measures Chosen for Analysis from
QD and ADNI. In the QD study, the SRT total recall (12
items, 6 trials) was the strongest predictor among the ﬁve
hypothesized neuropsychological predictors examined [3].
TheSRTwasnotdoneinADNI,butthecomparablemeasure
of total recall across 6 trials in the Auditory Verbal learning
Test (AVLT) was not used for study inclusion criteria and was
available. Informant report of the patient’s functioning using
the Pfeﬀer Functional Activities Questionnaire (FAQ) total
score and MRI hippocampal and entorhinal cortex volumes
was additional predictors in the ﬁnal model in QD [3] that
were also assessed in ADNI.
Both studies conducted MRI on 1.5T scanners: a single
GE scanner in QD, and GE or Siemens or Philips scanners
across 48 sites in ADNI. In QD, hippocampal volume was
assessed by a semiautomated method with speciﬁc anatomi-
cal landmarks used to deﬁne hippocampal boundaries, and
entorhinal cortex volume was computed from three slices
centered at the level of the mammillary bodies [7]. In
ADNI, MRI hippocampal and entorhinal cortex volumes
were derived from postprocessed image analysis that used
FreeSurfer (FS) version 4.3.0 by researchers at the University
of California, San Francisco (UCSFFSX); the data are
availableathttp://adni.loni.ucla.edu/.Thev olumederivation
p r o c e s si sd e s c r i b e da thttp://www.loni.ucla.edu/twiki/bin/
view/ADNI/ADNIPostProc. For both studies, intracranial
volume was a covariate in all analyses of hippocampal and
entorhinal cortex volumes.
2.4. Statistical Analyses. Summary statistics were calculated
to describe the sample characteristics in the ADNI and QD
studies. For each study, Chi-square and t-tests were usedInternational Journal of Alzheimer’s Disease 3
Table 1: Baseline sample characteristics of patients with MCI with three years of followup.
Variables Alzheimer’s Disease Neuroimaging Initiative (ADNI) Questionable Dementia (QD) study
Total
N = 282%
Nonconverter
N = 125%
Converter
N = 157%
Group
diﬀerence
Chi-square
P value
Total
(N = 126)
%
Not
converted
(N = 93)
%
Converted to
AD (N = 33)
%
Group
diﬀerence
Chi-square
P value
Gender (% Male) 67.02 76.0 59.87 0.0063 26.19 48.39 39.39 0.3154
Race (%)
Caucasian 92.20 92.00 92.36 0.8913 75.40 77.42 69.70 0.8452
Hispanic 2.84 2.40 3.18 16.67 15.05 21.21
African
American 2.48 2.40 2.55 5.56 5.38 6.06
Other 2.48 3.20 1.91 2.40 2.15 3.03
ApoE ε4 56.03 40.00 68.35 <0.0001 27.27 25.27 33.33 0.5332
Mean (SD) Mean (SD) Mean (SD) t-test Mean (SD) Mean (SD) Mean (SD) t-test
Age (years) 74.59 (7.30) 74.63 (7.66) 74.56 (7.03) 0.9351 67.31 (9.72) 65.24 (9.69) 73.12 (7.21) <0.0001
Education (years) 15.76 (2.88) 15.95 (2.81) 15.60 (2.94) 0.3074 15.18 (4.03) 15.58 (3.77) 14.06 (4.58) 0.0507
MMSE 27.08 (1.80) 27.62 (1.74) 26.66 (1.73) <0.0001 27.52 (2.21) 28.02 (1.99) 26.12 (2.20) <0.0001
AVLT/SRT 34.14 (10.90) 39.73 (12.16) 29.69 (7.16) <0.0001 42.66 (9.49) 45.60 (8.26) 34.09 (7.50) <0.0001
FAQ 2.84 (2.79) 1.61 (2.08) 3.82 (2.90) <0.0001 1.69 (2.05) 1.28 (1.84) 2.73 (2.21) 0.0002
N = 274 N = 120 N = 154 t-test N = 118 N = 89 N = 29 t-test
Hippocampal volume 6.30 (1.10) 6.78 (1.01) 5.92 (1.02) <0.0001 4.20 (0.73) 4.37 (0.62) 3.69 (0.74) <0.0001
Entorhinal cortex
volume 0.33 (0.08) 0.36 (0.07) 0.30 (0.07) <0.0001 0.45 (0.10) 0.47 (0.09) 0.38 (0.09) <0.0001
Intracranial volume 1580.79
(166.15)
1602.50
(152.48)
1563.69
(174.67) 0.0549 1306.60
(126.83)
1317.43
(128.55)
1273.71
(117.49) 0.0919
MMSE: Mini-Mental State Exam, AVLT: Auditory Verbal Learning Test (sum of 6 trials), SRT: Selective Reminding Task (sum of 6 trials), FAQ: Pfeﬀer’s
Functional Activities Questionnaire (10 items), SD: standard deviation, AD: Alzheimer’s disease. Hippocampal, entorhinal, and intracranial volumes are in
cubic centimeters. Entorhinal cortex volumes measured in cubic millimeters in ADNI were converted to cubic centimeters. Intracranial volume in ADNI
covered all intracranial structures including the cerebellum, but intracranial volume in QD was restricted to supratentorial intracranial volume.
to detect diﬀerences in baseline categorical and continuous
variables between MCI patients with and without transition
to AD by three years of followup (there were few non-
AD dementia cases in both studies). The QD and ADNI
studies had diﬀerent available followup duration times, and
therefore survival analysis was not used for comparisons.
For both datasets, speciﬁc sets of baseline predictors were
examined in logistic regression models for the binary
outcome of transition to AD within 3 years after baseline
evaluation. With each model, sensitivity and speciﬁcity
were calculated for all possible cut points on the predicted
risk of transition to AD to construct receiver operating
characteristic (ROC) curves. From the ROC curves, the area
under the curve (AUC) was compared statistically between
datasets and between nested models within each dataset.
3. Results
3.1. Demographic and Clinical Features of the Two Samples.
Compared to the QD sample, the ADNI sample was older,
had a greater proportion of males, had a higher proportion
with the apoE ε4 allele, and reported greater functional
impairment (Table 1). The samples did not diﬀer in years of
educational attainment and MMSE scores.
3.2. Prediction of Transition from MCI to AD by 3-Year
Followup. The majority of patients in ADNI (157/282 or
55.6%) and a minority of patients in QD (33/126 or 26.1%)
converted to AD by 3-year followup; the disparity likely
related to more stringent inclusion criteria for memory
impairment in ADNI compared to QD. Based on logistic
regression analyses, the combination of age and MMSE was
a poor predictor in ADNI and showed low sensitivity at the
ﬁxed level of 90% speciﬁcity in QD (top of Table 2). Models
that included age with MMSE and speciﬁc combinations
of AVLT or SRT total recall, FAQ scores, hippocampal and
entorhinal cortex volumes showed greater sensitivity, speci-
ﬁcity, and predictive accuracy in the QD study compared to
ADNI (Table 2).
3.3.ComparisonofAUCs. Three predictor models were com-
pared within and across studies with age and MMSE, which
are common clinical indicators, contained in all models.
Model 1 included AVLT/SRT and FAQ, Model 2 included
hippocampal and entorhinal cortex volumes, and Model 3
included AVLT/SRT, FAQ, and hippocampal and entorhinal
cortex volumes (Table 2). In each study, the increase in AUC
for Model 1 compared to Model 2 was marginal (around
0.04 in both studies) and not statistically signiﬁcant (bottom4 International Journal of Alzheimer’s Disease
Table 2: Predictive accuracy of speciﬁc combinations of predictor variables for classiﬁcation of transition to Alzheimer’s disease (AD) by 3
years of followup in two independent samples (ADNI and QD) of older adults with Mild Cognitive Impairment, and comparisons of three
predictor models.
ADNI QD
Model Predictor variables AUC (SE)
Sensitivity at
speciﬁcity =
80% (90%)
Correct
classiﬁcation % AUC (SE)
Sensitivity at
speciﬁcity =
80% (90%)
Correct
classiﬁcation %
Age 0.497 12.74 (5.73) 55.67 0.739 52.61 (29.85) 73.02
MMSE 0.655 37.88 (19.20) 65.54 0.778 41.41 (26.79) 76.00
Hippocampal vol. 0.725 48.05 (34.42) 64.60 0.753 62.07 (41.38) 80.51
Entorhinal volume 0.718 50.65 (35.71) 67.16 0.773 67.86 (50.00) 80.34
AVLT 0.756 49.47 (25.16) 44.33 0.849 71.63 (53.13) 80.00
FAQ 0.738 49.05 (35.90) 44.33 0.708 45.46 (32.83) 75.42
Age, MMSE 0.659 36.94 (18.79) 63.48 0.821 72.73 (39.39) 76.00
Hippocampal and
entorhinal volumes 0.744 55.84 (35.71) 68.98 0.824 67.86 (67.86) 88.03
AVLT/SRT and FAQ 0.811 62.74 (42.68) 72.70 0.879 78.13 (59.38) 82.05
Model 1 Age, MMSE, AVLT/SRT
and FAQ 0.828 (0.024) 73.25 (49.05) 73.40 0.921 (0.027) 90.63 (81.25) 87.07
Model 2
Age, MMSE,
Hippocampal and
entorhinal volumes
0.783 (0.028) 57.79 (40.26) 73.72 0.866 (0.046) 82.14 (71.43) 87.07
Model 3
Age, MMSE, AVLT/SRT,
FAQ, Hippocampal and
entorhinal volumes
0.865 (0.022) 75.33 (55.20) 77.01 0.940 (0.027) 92.59 (88.89) 89.72
Model comparisons AUC diﬀerence P value AUC
diﬀerence
P value
Model 1 versus Model 2 0.0396 0.2271 0.0428 0.3618
Model 1 versus Model 3 0.0428 0.0035∗∗ 0.0282 0.1979
Model 2 versus Model 3 0.0824 0.0001∗∗ 0.0710 0.0254∗
A threshold of 0.5 was used on predicted risk derived from the logistic regression models. Area under the curve (AUC) was derived from receiver operating
characteristic (ROC) analyses. N = 282 (157 converters) in ADNI and N = 126 (33 converters) in QD. The diﬀerences between models in AUCs are slightly
diﬀerent from the direct subtraction of AUCs between models because of missing data that ranged from 1% to 4% for the variables examined in ADNI and
1% to 5% for the variables examined in QD.
∗P<0.05, ∗∗P<0.01.
of Table 2). The AUC increased consistently across the
two studies when episodic verbal memory (AVLT/SRT)
and function (FAQ) measures were added to the model
containingthecombinationofage,MMSE,andhippocampal
andentorhinalcortexvolumes(P<0.0001inADNIandP =
0.0254 in QD; Model 2 versus Model 3, bottom of Table 2
and Figure 1), with an appreciable increase in sensitivity for
a ﬁxed speciﬁcity of 80% and 90% in both ADNI (increases
of 17% and 15%, resp.) and QD (increases of 10% and
1 7 % ,r e s p . ;t o po fTable 2 and Figure 1). Conversely, adding
hippocampal and entorhinal cortex volumes to AVLT/SRT,
FAQ, age, and MMSE signiﬁcantly increased the AUC in
ADNI (P = 0.0035) but not in QD (P = 0.20) and led to
a small increase in sensitivity for a ﬁxed speciﬁcity of 80%
and 90% in ADNI (increases of 2% and 6%, resp.) and QD
(increases of 2% and 7%, respectively, top of Table 2).
In both samples, the diﬀerences in AUCs between the
three statistical models examined were very similar (bottom
of Table 2). Analyses of all combinations of predictors exam-
ined are in the supplemental Table 3. (see Supplementary
Material available online at doi: 10.1155/2012/483469).
When the QD sample was restricted to patients with
baseline amnestic MCI (32/90 transitioned to AD) using
comparable criteria to ADNI inclusion criteria for amnestic
MCI, the results were similar to the entire QD sample: 80.7%
were correctly classiﬁed for Model 1, 85.5% for Model 2, and
84.2% for Model 3. AUCs were 0.877 for Model 1, 0.905 in
Model2,and0.915inModel3withoutsigniﬁcantdiﬀerences
in AUCs, partly because of reduced sample size.
4. Discussion
Within each sample, QD and ADNI, the diﬀerences in
AUCs between predictor models were similar, suggesting
robustness and generalizability across outpatient settings.International Journal of Alzheimer’s Disease 5
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Figure 1: Comparison of receiver operating characteristic (ROC curves) for three statistical models in the ADNI and QD studies. Model 1
(red line) contained age, MMSE, AVLT/SRT and FAQ, Model 2 (blue line) contained age, MMSE, hippocampal and entorhinal cortex
volumes, and Model 3 (green line) contained age, MMSE, AVLT/SRT, FAQ, hippocampal and entorhinal cortex volumes. The vertical lines
at 80% speciﬁcity (0.2 on x-axis) indicate 20% false positives.
When advising patients and families about the likelihood
of transition from MCI to AD, a predictor model with
speciﬁcityover80%isessentialbecauseafalsepositiverateof
over20%(speciﬁcitylessthan80%)isclinicallyunacceptable
[14, 15]. In the predictor model, adding hippocampal
and entorhinal cortex atrophy to age, MMSE, and the
episodic verbal memory and function measures increased
sensitivity only to a small extent at ﬁxed speciﬁcities of
80% and 90%. These ﬁndings suggest limited added utility
for MRI hippocampal and entorhinal cortex volumes to
clinical assessment of memory and function in predicting
transition from MCI to AD. In contrast, adding measures
of episodic verbal memory and function to the model that
combined age, MMSE, and hippocampal and entorhinal
cortex volumes appreciably increased sensitivity for ﬁxed
levels of 80% and 90% speciﬁcity in both samples. In
both studies, the model that included AVLT/SRT, FAQ, and
hippocampal and entorhinal cortex volumes with age and
MMSE showed the strongest predictive accuracy.
For episodic verbal memory measures, numerical ranges
and cutoﬀs for speciﬁc ages and education levels can inform
the likelihood of transition to AD. Although delayed recall
deﬁcit is typical in AD, both immediate recall (incorporates
learning) and delayed recall show comparable predictive
accuracy for the transition from MCI to AD [4]. The use of
a single episodic memory measure in the predictor models
examined does not replace the need for a comprehensive
neuropsychological evaluation for diagnostic purposes [4].
Informant reports of FAQ scores reﬂect instrumental, social,
and cognitive functional impairments, but speciﬁc cutoﬀs
for prediction of transition to AD are not established
[5, 16]. International eﬀorts to standardize MRI imaging
parametersandmethodsofvolumetricassessment[17],both
of which have varied widely across studies, may lead to
the development of speciﬁc cutoﬀs for hippocampal and
entorhinal cortex atrophy that improve predictive accuracy.
The use of cognitive markers has some advantages over
neuroimaging: objectivity in scoring, comparative economy
in expense and time, and reliability. One argument is that
episodic verbal memory should not be used as a marker
because it is used for inclusion criteria and in the diagnostic
process. However, evaluation of severity of episodic verbal
memory deﬁcit as a predictor in patients with amnestic MCI
who have episodic verbal memory deﬁcits is analogous to
the established strategy of evaluating severity of depression
as a predictor of clinical course and treatment response in
major depression [18]. Further, using memory test scores
in prediction creates a statistical handicap, rather than an
advantage, by restricting the range in baseline memory test
performance [12]. Of note, the AVLT memory measure
examined as a predictor in this paper was not part of the
study inclusion criteria in ADNI (WMS-R logical memory
was used). The same rationale applies to the incorporation
of the MMSE, which is widely used and clinically relevant,
in predictor analyses even though it is part of the screening
criteria for study inclusion.
Informant report of functional impairment using the
FAQ was not part of the inclusion criteria in either QD or
ADNI, and the deﬁnition of MCI by the original Peters-
en criteria requires the absence of signiﬁcant functional6 International Journal of Alzheimer’s Disease
impairment [1, 2]. Therefore, the use of informant report
of functional impairment is independent of the diagnostic
criteria for MCI, and our ﬁndings indicate that this type of
assessmentisimportant inpredicting transition toAD[3,5].
Clinical and neurobiological markers have been incor-
porated recently into diagnostic classiﬁcation systems. An
international panel used the terms “prodromal dementia”
and “predementia” to indicate that neurobiological markers
may identify patients with incipient AD who cannot be
diagnosed clinically [19]. The new NIA diagnostic criteria
separate core clinical criteria from research criteria that
employ neurobiological markers [20], partly because diag-
nostic and predictive accuracy for neurobiological markers
has not been fully developed and validated. Our results
emphasize the need for such validation.
There have been few comparisons of predictor models
betweenstudies.InacomparisonofADNItoaFinnishstudy,
classiﬁcation performance did not increase after the inclu-
sion of 10 variables that included CSF measures, apolipopro-
teinEε4,MRImeasur es,age,andeducation[21].Theoverall
model was not strong, possibly because key cognitive and
functionalmeasureswereexcluded.Anotherstudycompared
diﬀerent samples of patients with MCI who had 18FDG PET
with generally positive results [22] but without cut-points
for clinical application. Our report represents a novel inde-
pendentvalidationofpredictormodelsthatincludedclinical,
memory, functional, and MRI measures. The consistency in
the diﬀerences between models in each study indicates that
this two-study comparison is broader and more clinically
relevant than prior validation attempts [21, 22].
From the ADNI database, several reports show moderate
predictive accuracy for weighted scores within a global
cognitive test [23] and moderately strong predictive accuracy
for speciﬁc neuropsychological test scores [24], consistent
with other studies [4]. The best possible ﬁt from a high-
dimensional pattern classiﬁcation approach using ADNI
MRI data [25] led to results similar to our report that
used volumetric measures, but other MRI analytic strategies
using ADNI data have led to lower predictive accuracy
[26, 27]. Entorhinal cortex volume enhanced prediction in
both ADNI and QD in our comparisons, supporting the
evaluation of entorhinal cortex volume as a predictor [7].
There were some limitations to this paper. The two
samples diﬀered in sex and age distribution and cognitive
test scores, signiﬁcant episodic verbal memory deﬁcits were
required in ADNI compared to broader inclusion criteria
in QD that may partly account for higher transition rates
in ADNI, and diﬀerent episodic verbal memory measures
and diﬀerent MRI volumetric assessment methods were
compared. Nonetheless, within each sample for several
combinations of predictors the diﬀerences in AUCs were
similar. The high transition rate in ADNI suggests that
some patients diagnosed with MCI by 3-year followup may
convert in subsequent years, likely leading to a higher rate of
false negatives in ADNI. This may partly explain the lower
accuracy for predictor combinations in ADNI. In ADNI, the
smaller number of patients at 3-year followup was partly
related to some recently recruited patients not yet having
had the opportunity to reach 3-year followup at the time
of data analysis for this paper. This issue also precluded the
u s eo fs u r v i v a la n a l y s i si nt h i ss a m p l e .I nQ D ,w ed e r i v e d
the strongest predictors from a set of a priori measures
in a large neuropsychological test battery and examined
comparable measures from the shorter ADNI neuropsycho-
logical assessment. While administering a comprehensive
neuropsychological test battery is important for diagnostic
purposes, our clinically relevant approach of examining
individualmeasuresfacilitatescomparisonacrossstudiesand
demonstratesthepredictivestrengthofevenasingleepisodic
verbal memory test. Baseline MRI measures were examined
because serial MRI measures were not available in QD.
It remains unclear if serial imaging measures are superior
to baseline imaging in predicting long-term outcome [28].
Serial imaging measures provide useful information about
structural changes associated with disease progression, but
they are expensive, not current clinical practice, and not
useful in early converters. Cerebrovascular disease may
contribute to cognitive decline in these patients [19, 20].
However, hyperintensities, lacunes, and infarcts could not be
assessed systematically in QD because of the MRI sequences
obtained (no FLAIR or comparable sequence) and therefore
could not be compared with ADNI. Absent neuropathologi-
cal validation, we considered examining CSF measures from
ADNI (not done in QD) for in vivo validation of transition
to AD, but CSF was not collected in approximately half the
ADNI sample and neuropathological validation of CSF tau
and Aβ abnormalities has not been established.
In QD, the pathophysiological measure [19]o fo l f a c t o r y
identiﬁcation deﬁcits (not done in ADNI) strongly predicted
transition to AD with limited overlap in prediction with the
SRTandMRImeasures[3,29].InADNI, 18FDGindices(not
done in QD) signiﬁcantly predicted transition to AD and
were superior to the ADAS-cog [8], but the ADAS-cog is a
global cognitive measure used primarily in clinical trials of
AD patients and is not established as a strong predictor of
transition from MCI to AD. PET amyloid imaging discrim-
inates among AD, MCI, and controls [30] and correlates at
autopsy with amyloid plaques [9]. However, approximately
10–30% of healthy controls show increased amyloid uptake
[30] and whether these subjects have incipient AD needs
conﬁrmation in long-term followup studies. The sensitivity
and speciﬁcity of CSF levels of Aβ42 and tau/phospho tau,
and their ratio, for predicting MCI transition to AD in ADNI
[31] and in a European multicenter study [32]r a n g e df r o m
65%to75%,whichisslightlylowerthanthatinotherreports
[10, 11]. For CSF markers, further reﬁnement of assay
technique and validation in long-term followup studies are
needed to establish more deﬁnitive cut-points for individual
and ratio measures that have varied to some extent across
studies [10, 11, 32].
This report suggests that volumetric evaluation of medial
temporal lobe atrophy adds only marginally to the informa-
tion obtained by cognitive testing and assessment of episodic
memory, and it cannot yet be recommended for wide clinical
use to assess the risk of patients with MCI being diagnosed
with AD during followup. In the clinic, visual inspection
ratings are likely to lead to lower predictive accuracy than
either the QD or ADNI volumetric assessments. StructuralInternational Journal of Alzheimer’s Disease 7
neuroimaging with MRI remains useful to rule out speciﬁc
causes of cognitive impairment, for example, stroke, tumor.
A key conclusion from this report is that conducting neu-
ropsychological evaluation is important, and interviewing
family members or other informants about the patient’s
functioning may be at least as important as conducting
an MRI scan. Several clinical and neurobiological markers,
including cognitive test scores, functional ability, and MRI
and 18FDGPETmeasures,areinﬂuencedconsiderablybyage
and other demographic factors, and their utility needs to be
evaluated in more heterogeneous samples. The comparative
predictive utility of clinical and neurobiological markers
needs further assessment across diﬀerent populations as
these measures improve in predictive accuracy.
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